Catalent launches integrated suite for biologics

Contract drug manufacturer Catalent has launched a new integrated suite of equipment to help address challenges facing biologic development.

The company launched its OneBio Suite at BIO International Convention earlier in June. The suite has been designed to accelerate biologics to clinic or market and offer companies greater simplicity in the development process, including fewer internal resource needs and a reduced risk of rework.

As an integrated offering, Catalent Biologics’ OneBio Suite will aim to reduce timelines, risk and complexity by providing customers with a single contract, programme manager, and development timeline from cell line to clinical supply.

“Time is often lost for sponsors on the path to clinic from contract negotiation, site inspections, handoffs, and poor communication between multiple vendors,” commented Bernie Clark, vice president, marketing & strategy, Catalent Biologics & Specialty Drug Delivery. “Through our new OneBio Suite, Catalent is uniquely positioned to provide an integrated offering that can accelerate biologic development potentially shaving weeks to months off standard timelines and allowing our customers to get to clinic and market faster.”